Navigation Links
Landmark dental school study uses genetic test to help predict gum disease
Date:8/12/2010

ANN ARBOR, Mich.---University of Michigan School of Dentistry has signed an agreement with Interleukin Genetics Inc. to conduct what may be the largest clinical study to date using genetic testing to assess the risk for gum disease.

William Giannobile, professor at U-M dentistry and director of the Michigan Center for Oral Health Research at the School of Dentistry, will lead the study for U-M.

"It's an exciting study because it's a way to use genetic testing to personalize a dental treatment plan and the frequency of dental care visits of patients as it relates to oral care," said Giannobile. "It's a way to customize patient care."

"One of the goals of personalized health care is to detect disease earlier and prevent it more effectively," said Kenneth Kornman, president and chief scientific officer of Waltham, Mass. based-Interleukin. The study will use Interleukin's PST test as one part of a periodontitis risk assessment, said Kornman, who is also an alumnus of the U-M Dental School. Research has shown that genetics plays a large role in gum disease, and research also suggests that severe gum disease is a risk factor for other chronic disease complications such as heart disease or low birth weight.

U-M scientists will examine 15 years of patient clinical outcome data provided by a Michigan-based insurance company. Scientists will then recruit at least 4,000 of those patients and get their genetic information using the PST, Giannobile said.

They will combine this genetic information with two other common risk factors, smoking and diabetes, then measure tooth survival rates to see how those results lined up with the treatment plans people received over the 15 years. Some patients may have needed more dental visits, some may have required less, Giannobile said.

The PST genetic test works by identifying genetic variations that are predictive of severe gum disease and tooth loss in some patients. The test may be used on all ethnic populations and must only be given once in a lifetime to identify at-risk patients. Specifically, the test identifies genetic variants that regulate a protein that when overexpressed, is thought to be associated with destruction of soft tissue attachment and bone and increased severity of gum disease in certain patients.

Interleukin's test can be used in dental offices and is available in all U.S. states including New York, which monitors the accuracy and reliability of results of laboratory tests and sets one of the highest accreditation standards in the country for genetic testing companies. The company hopes the study results establish reimbursement coverage for the test. The insurance company would not have access to any genetic information, Giannobile said. The information would allow the dentist to make a more informed treatment protocol.

An estimated 75 percent of American adults have some form of gum disease, and roughly 20-25 percent have moderate to severe cases which can lead to tooth loss. The year-long study begins in the fall.


'/>"/>

Contact: Laura Bailey
baileylm@umich.edu
734-647-1848
University of Michigan
Source:Eurekalert

Related biology news :

1. Landmark study unlocks stem cell, DNA secrets to speed therapies
2. Landmark national study reveals significance of green practices in attractions industry
3. 150 years of Darwins landmark book spawns international conference
4. ACLU -- Myriad Genetics lawsuit will become landmark case
5. Landmark project to map genomics of complex ant systems
6. Carnegie donates landmark clones to biology
7. Scripps Research team wins global race to achieve landmark synthesis of perplexing natural product
8. Moa get fewer: Landmark study
9. Lower your blood pressure, hydrate your skin and reduce dental plaque -- with chocolate?
10. Eastman Dental Center awarded $1.6 million to find ways to prevent cavities
11. New generation of orthopedic, dental and cardiovascular prostheses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):
(Date:5/3/2016)... , ... May 03, 2016 , ... ... enterprise talent development, skill-building and compliance training platform on mobile devices, today released ... Overview of Regulatory Requirements for Medical Devices. The course is essential for owners ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... unique bioresearch materials from laboratories across the globe, today announced the availability of ... the pace of research toward treatment and prevention measures for the Zika virus, ...
(Date:5/3/2016)... York, NY (PRWEB) , ... May 03, 2016 , ... ... Hill Hospital , for definitive prostate cancer treatment, patients traditionally had two main treatment ... appropriate treatment plan would be made. , New technology has enabled doctors to ...
(Date:5/2/2016)... ... May 02, 2016 , ... StarNet Communications Corp, ( http://www.starnet.com/ ) a leading ... Secure Remote Desktop modules to its flagship X-Win32 PC X server. The new ... to the user’s PC over encrypted SSH. , Traditionally, users of PC X servers ...
Breaking Biology Technology: